The Medical Letter on Drugs and Therapeutics
Cariprazine (Vraylar) for Schizophrenia and Bipolar I Disorder
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved cariprazine (Vraylar – Actavis), an oral, once-daily, second-generation antipsychotic, for treatment of schizophrenia and for acute treatment of manic or mixed episodes associated with bipolar I disorder.

STANDARD TREATMENT — With the exception of clozapine (Clozaril, and others), second-generation antipsychotics are not clearly more effective than first-generation antipsychotics for treatment of schizophrenia, but in usual doses they are much less likely to cause tardive dyskinesia. Clozapine is usually reserved for refractory disease because of its potential for serious toxicity, including seizures and agranulocytosis. Olanzapine (Zyprexa, and generics) may be the most effective of the other second-generation antipsychotics, but it is also the most likely to cause metabolic adverse effects. Patients who do not respond to one antipsychotic may respond ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Cariprazine (Vraylar) for Schizophrenia and Bipolar I Disorder
Article code: 1493b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian